Cure8 trial brief
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if further studies show benefit.
Safety findings and eligibility rules are important for patients thinking about trial participation or future treatment options.
Adults with moderately to severely active ulcerative colitis, gastroenterologists and IBD clinicians, clinical researchers in IBD drug development, and patients considering participation in investigational-drug trials.
This trial is an early-phase (Phase 1) safety study adding aletekitug, an investigational anti–IL-18 antibody, to a platform trial for moderate-to-severe UC. The main goals are to measure adverse events and tolerability rather than efficacy; planned enrollment is small (≈16 participants).
If you have UC, the study requires endoscopic proof of active disease beyond the rectum and excludes people with prior colectomy, ostomy/ileoanal pouch, recent biologic or small-molecule advanced therapies, recent serious infections, or certain other medical conditions. Women of childbearing potential must meet contraception rules.
If you’re considering trial participation, the registry entry lists detailed inclusion/exclusion criteria and the safety-focused outcome measures; discuss trial suitability, risks, and alternatives with your gastroenterologist or the study team.
Phase 1 trials are primarily designed to assess safety in a small number of participants and do not provide definitive evidence of benefit. This record is a trial registration (not a study result); eligibility and exclusion criteria are strict and listed on the ClinicalTrials.gov page.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
